BIRC7 Antikörper (AA 1-265)

Produktnummer ABIN7145211

Der Kaninchen Polyklonal Anti-BIRC7-Antikörper wurde für WB und ELISA validiert. Er ist geeignet, BIRC7 in Proben von Human zu detektieren.

Kurzübersicht für BIRC7 Antikörper (AA 1-265) (ABIN7145211)

Target: BIRC7 (Baculoviral IAP Repeat-Containing 7 (BIRC7))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser BIRC7 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA

Produktdetails anti-BIRC7 Antikörper

Bindungsspezifität: AA 1-265

Kreuzreaktivität: Human

Aufreinigung: Antigen Affinity Purified

Immunogen: Recombinant Human Baculoviral IAP repeat-containing protein 7 protein (1-265AA)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Recommended dilution: WB:1:200-1:1000,

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: PBS with 0.02 % sodium azide, 50 % glycerol, pH 7.3.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Details zu BIRC7

Target: BIRC7 (Baculoviral IAP Repeat-Containing 7 (BIRC7))

Andere Bezeichnung: BIRC7

Hintergrund:

Background: Apoptotic regulator capable of exerting proapoptotic and anti-apoptotic activities and plays crucial roles in apoptosis, cell proliferation, and cell cycle control. Its anti-apoptotic activity is mediated through the inhibition of CASP3, CASP7 and CASP9, as well as by its E3 ubiquitin-protein ligase activity. As it is a weak caspase inhibitor, its anti-apoptotic activity is thought to be due to its ability to ubiquitinate DIABLO/SMAC targeting it for degradation thereby promoting cell survival. May contribute to caspase inhibition, by blocking the ability of DIABLO/SMAC to disrupt XIAP/BIRC4-caspase interactions. Protects against apoptosis induced by TNF or by chemical agents such as adriamycin, etoposide or staurosporine. Suppression of apoptosis is mediated by activation of MAPK8/JNK1, and possibly also of MAPK9/JNK2. This activation depends on TAB1 and NR2C2/TAK1. In vitro, inhibits CASP3 and proteolytic activation of pro-CASP9. Isoform 1 blocks staurosporine-induced apoptosis. Isoform 2 blocks etoposide-induced apoptosis. Isoform 2 protects against natural killer (NK) cell killing whereas isoform 1 augments killing.

Aliases: Baculoviral IAP repeat containing 7 antibody, Baculoviral IAP repeat containing protein 7 antibody, Baculoviral IAP repeat-containing protein 7 antibody, BIRC 7 antibody, birc7 antibody, BIRC7_HUMAN antibody, KIAP antibody, Kidney inhibitor of apoptosis protein antibody, Livin antibody, Livin inhibitor of apotosis antibody, Melanoma inhibitor of apoptosis protein antibody, ML IAP antibody, ML-IAP antibody, MLIAP antibody, RING finger protein 50 antibody, RNF 50 antibody, RNF50 antibody

UniProt: Q96CA5